The development of gene therapies for the treatment of cancer has generally relied upon two strategies. The first is the expression of a therapeutic transgene from a replication-defective (RD) viral ...
Genetic instability of cancer cells generates resistance after initial responses to chemotherapeutic agents. Several oncolytic viruses have been designed to exploit specific signatures of cancer cells ...
Preclinical Data Shows the Robust Anti-Tumoral Activity of BT-001, Including Its Highly Effective and Safe Therapeutic Strategy of Targeting CLTA-4 LUND, SE / ACCESSWIRE / March 8, 2022 /BioInvent ...
BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer ...
Oncolytic herpes simplex virus type I (HSV-1) vectors are promising therapeutic agents for cancer. Their efficacy depends on the extent of both intratumoral viral replication and induction of a host ...
LUND, Sweden and STRASBOURG, France, Nov 7, 2018 /PRNewswire/ -- BioInvent International AB (OMXS: BINV), focused on the discovery and development of novel and first-in-class immuno-regulatory ...
Boosting of cellular and humoral immune responses to HPV16/18 antigens by VGX-3100: A follow-on phase I trial. A first-in-class, first-in-human phase I study of enadenotucirev, an oncolytic Ad11/Ad3 ...
STRASBOURG, France & LUND, Sweden--(BUSINESS WIRE)--Regulatory News: Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against ...
The field of immuno-oncology is exciting for investors, patients and physicians, with a daily drum beat of new efforts being undertaken to battle cancer. Add Oncorus to that growing chorus. The ...
STRASBOURG, France & LUND, Sweden--(BUSINESS WIRE)--Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, and ...
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, and BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a ...
Transgene and BioInvent Joint JITC Publication Demonstrates the Potential of BT-001 Oncolytic Virus to provide therapeutic benefit beyond current anti-PD1/ anti-CTLA-4 immune checkpoint blockade ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback